Kraig Biocraft Laboratories, Inc. (KBLB.OB) Reports Noteworthy Progress in Development of Site Specific Genetic Recombination
Kraig Biocraft Laboratories, Inc. announced this morning that Dr. Fraser’s team has "made significant progress on developing enzymes and strategies for conducting site specific genetic recombination in silkworm." "In the Company's view, the development of this particular gene splicing technology is the key to unlocking the tremendous commercial potential of spider silks and other recombinant polymers," stated Kraig's CEO, Kim K. Thompson. "Dr. Fraser's report of this news from the laboratory is the culmination of years of scientific effort. It is a huge milestone on the path to commercialization," continued Thompson. "We believe that we are the only people who…